KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Emergent BioSolutions (EBS) EBIT (2016 - 2026)

Emergent BioSolutions has reported EBIT over the past 16 years, most recently at $10.5 million for Q1 2026.

  • For Q1 2026, EBIT fell 78.96% year-over-year to $10.5 million; the TTM value through Mar 2026 reached $60.7 million, up 161.56%, while the annual FY2025 figure was $100.1 million, 192.09% up from the prior year.
  • EBIT for Q1 2026 was $10.5 million at Emergent BioSolutions, up from -$27.9 million in the prior quarter.
  • Over five years, EBIT peaked at $76.5 million in Q3 2025 and troughed at -$292.9 million in Q2 2023.
  • A 5-year average of -$52.6 million and a median of -$27.9 million in 2025 define the central range for EBIT.
  • Biggest five-year swings in EBIT: plummeted 2239.13% in 2023 and later skyrocketed 126.96% in 2024.
  • Year by year, EBIT stood at -$55.3 million in 2022, then grew by 20.8% to -$43.8 million in 2023, then surged by 78.31% to -$9.5 million in 2024, then crashed by 193.68% to -$27.9 million in 2025, then skyrocketed by 137.63% to $10.5 million in 2026.
  • Business Quant data shows EBIT for EBS at $10.5 million in Q1 2026, -$27.9 million in Q4 2025, and $76.5 million in Q3 2025.